- Paramount: UK Competition and Markets Authority approves Paramount Skydance's acquisition of Warner Bros.
- GRIFFON CORPORATION <GFF.N>: RAYMOND JAMES RAISES TARGET PRICE TO $125 FROM $115
- BNY to Add Staking for Institutional Clients to Digital Asset Custody Platform
- DYNATRACE, INC <DT.N>: ROSENBLATT SECURITIES RAISES TARGET PRICE TO $62 FROM $52
- EBAY <EBAY.O>: BENCHMARK RAISES TARGET PRICE TO $134 FROM $115
- Vecima elevates Clay McCreery to president, COO
- Electra Battery Materials backs US black mass export curbs to bolster domestic refining capacity
- Mangoceuticals merger partner Nuclea signs MOU with New Mining on modular reactor power for data centers
- SAB Biotherapeutics Q2 FY26 net loss widens to $22.5 million; R&D expenses more than doubled to $16.2 million
- Distribution Solutions Group FY26 Q2 net income rises 69.8% to $8.49 million; revenue climbs 11% to $557.73 million
- Suburban Propane FY26 Q3 net loss widens to $17.5 million; adjusted EBITDA drops to $18 million
- Frontdoor Q2 revenue rises 5%, slightly beats estimates
- Ethereum researchers want to burn staking rewards gradually
- Winshear Metals extends high-grade nickel-copper-cobalt mineralization at Portsoy project in Scotland
- SHOPIFY INC. <SHOP.O>: DEUTSCHE BANK RAISES TARGET PRICE TO $185 FROM $175
- Nayax files Connecticut application for US innovation bank charter
- PepGen advances PGN-EDODM1 into 12.5 mg/kg cohort in Phase 2 FREEDOM2-DM1 trial
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. <CRL.N>: JEFFERIES RAISES TARGET PRICE TO $305 FROM $225
- Installed Building Products FY26 Q2 net income drops 5.94% to $64.9 million; revenue rises 2.3% to $777.8 million
- Parker Hannifin FY26 Q4 adjusted EPS climbs 21% to $9.27; net sales rise 10% to $5.76 billion
- PAYCOM SOFTWARE, INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $205 FROM $140
- Kelly Q2 FY26 net earnings drop 40% to $11.4 million; revenue falls 5.8% to $1.04 billion
- NetScout FY27 Q1 GAAP net income turns to USD 21.8 million; revenue rises 12.7% to USD 210.4 million
- Parker-Hannifin Sees FY Organic Sales Growth of 5.5% to 8.5% >PH
- APPLOVIN CORPORATION : RAYMOND JAMES CUTS TARGET PRICE TO $590 FROM $640
- Sunstone Hotel Investors Q2 FY26 net income attributable to common stockholders more than doubled to $26 million; RevPAR rises 9.3% to $263.61
- MACOM FY26 Q3 GAAP net income more than doubled to $100.71 million; revenue rises 35.8% to $342.2 million
- PepGen Q2 FY26 net loss narrows 22.84% to $17.81 million
- ZIMMER BIOMET HOLDINGS, INC. <ZBH.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $98 FROM $88
- Parker-Hannifin Sees FY Reported Sales Growth of 5.5% to 8.5% >PH
- BRIEF-PepGen Q2 EPS USD -0.26
- Payoneer Q2 FY26 turns to net loss of USD 2.44 million; revenue rises 5% to USD 274.3 million
- BCM Resources drills 550-meter porphyry-skarn mineralized interval at Utah Thompson Knolls project
- Sunrise Realty Trust Q2 FY26 net income falls 8.41% to $3.08 million; interest income rises 26.8% to $8.56 million
- ATI Q2 2026 adjusted EBITDA climbs 37% y/y to $284 million; revenue rises 11% y/y to $1.3 billion
- Priority Technology Q2 net income falls 9.3% to $9.9 million; revenue rises 9.4% to $262.3 million
- Orion Digital Q2 FY26 swings to net loss of CAD 744,000; revenue slips 0.46% to CAD 16.86 million
- Arianne Phosphate’s Lac à Paul project joins Quebec government’s Filon fast-track support program
- Evolent Health Q2 revenue beats expectations
- Distribution Solutions 2Q Adj EPS 47c >DSGR
- Kelly Services 2Q Rev $1.04B >KELYA
- Kelly Services 2Q Net $11.4M >KELYA
- Kelly Services 2Q EPS 31c >KELYA
- Distribution Solutions 2Q Rev $557.7M >DSGR
- Sunstone Hotel Investors 2Q Net $25.9M >SHO
- Cronos Group 2Q EPS 9c >CRON.T
- Cronos Group 2Q Net $35.7M >CRON.T
- Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 million
- FrontView REIT Q2 adjusted FFO per share rises
- CME Group declares Q3 dividend of $1.3 a share
- Genie Energy 2Q26 net income more than quadruples to $11.4 million; revenue falls 4.7% to $100.4 million
- Abeona Therapeutics schedules conference call on Q2 2026 results
- BRIEF-Cronos Group Q2 Gross Profit USD 28.5 Million
- BRIEF-Lexicon Pharmaceuticals Q2 EPS USD -0.07
- BRIEF-Kelly Services Q2 Adjusted EPS USD 0.37
- BRIEF-Nuvation Bio Q2 EPS USD -0.18
- BRIEF-Cars.com Q2 Revenue USD 179.9 Million Vs. IBES Estimate USD 180.5 Million
- BRIEF-MACOM Technology Solutions Q3 Revenue USD 342.237 Million Vs. IBES Estimate USD 335.4 Million
- BRIEF-Parker-Hannifin Q4 Adjusted EPS USD 9.27 Vs. IBES Estimate USD 8.27
- MACOM Technology 3Q Adj EPS $1.40 >MTSI
- SAB Biotherapeutics 2Q Loss $22.5M >SABS
- MACOM Technology Sees 4Q Adj EPS $1.97-Adj EPS $2.03 >MTSI
- Distribution Solutions 2Q EPS 18c >DSGR
- Compass Therapeutics 2Q Loss $25.2M >CMPX
- MACOM Technology 3Q Rev $342.2M >MTSI
- Installed Building 2Q EPS $2.43 >IBP
- Parker-Hannifin Sees FY Adj EPS $34.25-Adj EPS $35.25 >PH
- Installed Building 2Q Adj EPS $2.91 >IBP
- Installed Building 2Q Rev $777.8M >IBP
- Sunstone Hotel Investors 2Q EPS 14c >SHO
- Sunstone Hotel Investors 2Q Rev $277.1M >SHO
- Priority Tech Holdings 2Q EPS 12c >PRTH
- Parker-Hannifin 4Q Sales $5.8B >PH
- Parker-Hannifin 4Q Net $1.09B >PH
- Parker-Hannifin 4Q Adj EPS $9.27 >PH
- Parker-Hannifin Sees FY EPS $30.00-EPS $31.00 >PH
- Parker-Hannifin 4Q EPS $8.54 >PH
- NetScout Systems 1Q Rev $210.4M >NTCT
- NetScout Systems 1Q Adj EPS 52c >NTCT
- Lexicon Pharma 2Q Rev $692,000 >LXRX
- Lexicon Pharma 2Q Loss $31.8M >LXRX
- ITT Inc 2Q Net $84.9M >ITT
- ITT Inc Sees FY Cont Ops EPS $4.47-EPS $4.67 >ITT
- ITT Inc Sees FY Adj EPS $8.12-Adj EPS $8.32 >ITT
- Collegium Pharmaceutical 2Q Loss/Shr 46c >COLL
- Priority Tech Holdings 2Q Rev $262.3M >PRTH
- MEDLINE INC. <MDLN.O>: STIFEL CUTS TARGET PRICE TO $45 FROM $50
- UACJ raises FY2026 operating profit forecast to ¥85 billion
- LCI INDUSTRIES <LCII.N>: STIFEL CUTS TARGET PRICE TO $130 FROM $137
- Banca Sistema 1H26 net income drops 69% y/y to €4.5 million
- PAYCOM SOFTWARE, INC. : STIFEL RAISES TARGET PRICE TO $200 FROM $120
- Mobix Labs announces investor strategic update call
- KRATOS DEFENSE & SECURITY SOLUTIONS, INC. <KTOS.O>: STIFEL CUTS TARGET PRICE TO $115 FROM $134
- POWER INTEGRATIONS, INC. : STIFEL CUTS TARGET PRICE TO $80 FROM $95
- INSULET CORPORATION : STIFEL CUTS TARGET PRICE TO $180 FROM $225
- SOLVENTUM CORPORATION <SOLV.N>: STIFEL RAISES TARGET PRICE TO $100 FROM $90
- Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders
- D-Wave Q2 FY26 net loss narrows 71.31% to $48 million; revenue flat at $3.1 million
- Amundi trims Munich Re voting rights to 2.97% from 3.16%
- FRESHPET, INC. <FRPT.O>: STIFEL RAISES TARGET PRICE TO $78 FROM $66
